← Leaderboards
Paola Gilsanz
Kaiser Foundation Research Institute
$24,690,756
Attributed
$59,114,639
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $20.3M · FY2012–25$25M$18.8M$12.5M$6.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$69,847,114 · 9
By mechanism
R01$56,891,606 · 5
P01$12,888,294 · 3
F31$67,214 · 1
Top collaborators
- Rachel A Whitmer12 shared
- Medellena Maria Glymour7 shared
- Elizabeth Rose Mayeda5 shared
- Maria Corrada4 shared
- Jacqueline Marie Torres2 shared
Most similar at Kaiser Foundation Research Institute
Same institution · by research overlap
- Rachel A Whitmer$36,362,887
- Mary Helen Black$795,568
- Jennifer Lam$713,340
- Anny H Xiang$8,218,850
- Matthew P Banegas$2,368,333
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS Disease Related DementiaCohortDementiaS Disease RiskAging BrainRisk FactorsImpaired CognitionElderlyS DiseaseIncidenceAdultCaliforniaEducationProtective FactorsParticipantComorbidityCognitive AgingPublic HealthPositron-Emission TomographyDementia RiskNerve DegenerationBlood VesselsExposure To
Grant awards (30)
Improving causal inference in Alzheimer's Disease prevention research on modifiable risk factors: the Triangulation of Innovative Methods to EndAD (TIME-AD) project$5,470,174
P01 · FY2025 · AG
Epidemiology of Age-related Dementia, Mild Cognitive Impairment and Brain Pathology in Cohort of Oldest-Old$5,105,538
R01 · FY2025 · AG
Study of Healthy Aging in African Americans$4,747,819
R01 · FY2025 · AG
Lifecourse health, cerebral pathology and differences in dementia risk (KHANDLE Study)$3,544,754
R01 · FY2025 · AG
Project 2: Depression and chronic pain: Modifiable targets for prevention of AD/ADRD$611,198
P01 · FY2025 · AG · contact PI
Core C: Maximizing Population Impact Core$570,319
P01 · FY2025 · AG · contact PI
Improving causal inference in Alzheimer's Disease prevention research on modifiable risk factors: the Triangulation of Innovative Methods to EndAD (TIME-AD) project$5,262,301
P01 · FY2024 · AG
Epidemiology of Age-related Dementia, Mild Cognitive Impairment and Brain Pathology in a Multiethnic Cohort of Oldest-Old$5,224,302
R01 · FY2024 · AG
Study of Healthy Aging in African Americans$4,846,194
R01 · FY2024 · AG
Lifecourse health, cerebral pathology and ethnic disparities in dementia (KHANDLE Study)$3,627,096
R01 · FY2024 · AG
Project 2: Depression and chronic pain: Modifiable targets for prevention of AD/ADRD$581,589
P01 · FY2024 · AG · contact PI
Equity and Dissemination Core$392,713
P01 · FY2024 · AG · contact PI
Glycemic Control and Dementia: The Role of Pharmacotherapy and Vascular Complications$389,396
R01 · FY2024 · AG · contact PI
Epidemiology of Age-related Dementia, Mild Cognitive Impairment and Brain Pathology in a Multiethnic Cohort of Oldest-Old$5,187,231
R01 · FY2023 · AG
Study of Healthy Aging in African Americans$4,646,209
R01 · FY2023 · AG
Lifecourse health, cerebral pathology and ethnic disparities in dementia (KHANDLE Study)$3,620,096
R01 · FY2023 · AG
Glycemic Control and Dementia: The Role of Pharmacotherapy and Vascular Complications$389,396
R01 · FY2023 · AG · contact PI
Contributions of educational quality and occupational complexity on racial and ethnic inequities in brain health and Alzheimer's disease and related dementia$353,269
R01 · FY2023 · AG · contact PI
Epidemiology of Age-related Dementia, Mild Cognitive Impairment and Brain Pathology in a Multiethnic Cohort of Oldest-Old$5,163,761
R01 · FY2022 · AG
Lifecourse health, cerebral pathology and ethnic disparities in dementia (KHANDLE Study)$3,627,096
R01 · FY2022 · AG
Glycemic Control and Dementia: The Role of Pharmacotherapy and Vascular Complications$389,396
R01 · FY2022 · AG · contact PI
Contributions of educational quality and occupational complexity on racial and ethnic inequities in brain health and Alzheimer's disease and related dementia$353,269
R01 · FY2022 · AG · contact PI
Lifecourse health, cerebral pathology and ethnic disparities in dementia (KHANDLE Study)$3,603,025
R01 · FY2021 · AG
Glycemic Control and Dementia: The Role of Pharmacotherapy and Vascular Complications$389,396
R01 · FY2021 · AG · contact PI
Contributions of educational quality and occupational complexity on racial and ethnic inequities in brain health and Alzheimer's disease and related dementia$353,269
R01 · FY2021 · AG · contact PI
Contributions of educational quality and occupational complexity on racial and ethnic inequities in brain health and Alzheimer's disease and related dementia$478,456
R01 · FY2020 · AG · contact PI
Glycemic Control and Dementia: The Role of Pharmacotherapy and Vascular Complications$376,789
R01 · FY2020 · AG · contact PI
Contributions of educational quality and occupational complexity on racial and ethnic inequities in brain health and Alzheimer's disease and related dementia$475,849
R01 · FY2019 · AG · contact PI
Short and long term depressive symptoms and arrhythmic pathways to stroke$30,245
F31 · FY2013 · HL · contact PI
Short and long term depressive symptoms and arrhythmic pathways to stroke$36,969
F31 · FY2012 · HL · contact PI